PRM A activates an immune response on the alpha cell to release glucagon. We are driven to provide this new mechanism of action that acts autonomously to release glucagon as needed without causing hyperglycemia. We are driving a "game changer" in diabetes management enabling glycemic control as an adjunct oral therapy to insulin. We are addressing a patient population of 100 million people with a target product profile that is oral, safe, accessibl and highly efficacious at low doses.

A novel undisclosed Oral treatment for Obesity. We have target validation for a once daily oral Obesity treatment that may enable a new way to treat millions of people with Obesity. Our new mechansim of action supports a target product profile that is safe, accessible, affordable and oral. We are advancing INDe studies to provide a clinical candidate that will be highly differentiated.

We have differentiated preclinical data on several of our candidates in mono and fixed dose Combination therapy showing remarkable glucose lowering and synergystic effects. These studies were conducted in acute and chronic studies over multiple relevant animal models.

Our discovery program includes proof of concept mechanistic studies over several of our candidates that showed unique liver activation that may lend itself to a novel therapy in NASH. This encouraging data is further supported by what we know about the target.

Alpha cell and Beta cell dysfunction is associated with cardiovascular disease. Our novel mechansim of action and molecular library may offer insight into intervention through pathways not previously explored.

Our IP position covers GPR119 dysregulation which may address certain neurodegenerative conditions. As we explore our highly targeted molecular library and new mechanism of action we plan to advance candidates.

Metabolic dysregulation can lead to certain cancers. Our new mechanism of action may enable the development of therapeutics to treat cancers via novel pathways that our candidates activate.